PEPFAR disruptions harm HIV services
Analysis based on 68 articles · First reported Jul 21, 2026 · Last updated Jul 31, 2026
The disruptions to PEPFAR undermine global HIV control efforts, potentially increasing long-term healthcare costs and destabilizing health systems in affected countries. Pharmaceutical companies supplying antiretrovirals may face reduced demand, while public health spending could shift to other donors.
A new report by AmfAR, The Foundation for AIDS Research, released on July 21, 2026, details widespread disruptions to the United States — President s Emergency Plan for AIDS Relief (PEPFAR) caused by the Trump administration's dismantling of the U.S. Agency for International Development (USAID) and cuts to global health grants. The survey of 166 organizations from 46 countries found that most had awards terminated or payments delayed, leading to the closure of over 1,700 clinics and loss of more than 16,000 staff. HIV prevention spending fell 51% from fiscal years 2024 to 2025. Services for key populations such as sex workers and men who have sex with men were disproportionately cut. A separate study in Nature Health found nearly 2 million fewer people received antiretroviral treatment in fiscal year 2025, a 10% decline. The U.S. State Department disputed the severity, citing stable treatment numbers for one quarter, but researchers combining data found substantial disruptions. AmfAR recommended restoring all HIV services and increasing funding from other governments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard